pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
KPT-8602
Phase 2 · small molecule · Relapsed/Refractory Multiple Myeloma (RRMM)
KPT-8602 for Relapsed/Refractory Multiple Myeloma (RRMM) is a Phase 2 program (small_molecule) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code KCP-8602-801
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- completed
- Trials
- 1